In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
MIT’s Recursive Language Models rethink AI memory by treating documents like searchable environments, enabling models to ...
Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback